{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:25:19Z","timestamp":1774632319194,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["1033"],"award-info":[{"award-number":["1033"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.leukres.2023.107021","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T02:07:52Z","timestamp":1674266872000},"page":"107021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"126","author":[{"given":"Fatemeh","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golale","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shafiei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Bahmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.leukres.2023.107021_bib1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2023.107021_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2011","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107021_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bcmd.2011.11.001","article-title":"ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib","volume":"48","author":"Vivona","year":"2012","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.leukres.2023.107021_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/labmed\/lmab023","article-title":"Association of SLC22A1, SLCO1B3 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in patients with chronic myeloid leukemia","author":"Mohammadi","year":"2021","journal-title":"Lab. Med."},{"issue":"13","key":"10.1016\/j.leukres.2023.107021_bib5","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/cncr.30636","article-title":"Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death","volume":"123","author":"Lauseker","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2023.107021_bib6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s13277-015-3874-4","article-title":"Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia","volume":"37","author":"Salimizand","year":"2016","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107021_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-407","article-title":"Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study","volume":"9","author":"Andersen","year":"2009","journal-title":"BMC Cancer"},{"issue":"S1","key":"10.1016\/j.leukres.2023.107021_bib8","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/01.HS9.0000562964.05114.68","article-title":"PS1170 Influx\/Efflux transporter in Chronic Myeloid Leukemia: the influence of genetic variants on susceptibility and drug response","volume":"3","author":"Alves","year":"2019","journal-title":"HemaSphere"},{"issue":"3","key":"10.1016\/j.leukres.2023.107021_bib9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/03602530600727947","article-title":"Human ABC transporter ABCG2 in xenobiotic protection and redox biology","volume":"38","author":"Wakabayashi","year":"2006","journal-title":"Drug Metab. Rev."},{"issue":"3","key":"10.1016\/j.leukres.2023.107021_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1179\/1607845413Y.0000000102","article-title":"Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients","volume":"19","author":"Elghannam","year":"2014","journal-title":"Hematol"},{"issue":"1","key":"10.1016\/j.leukres.2023.107021_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs-2016-0103","article-title":"Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis","volume":"18","author":"Jiang","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.leukres.2023.107021_bib12","first-page":"169","article-title":"ABCB1 genetic variants in leukemias: current insights into treatment outcomes","volume":"10","author":"Ankathil","year":"2017","journal-title":"Pharmacog. Pers. Med."},{"issue":"3","key":"10.1016\/j.leukres.2023.107021_bib13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopha.2014.01.009","article-title":"Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients","volume":"68","author":"Au","year":"2014","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.leukres.2023.107021_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2133\/dmpk.23.223","article-title":"Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs","volume":"23","author":"Maeda","year":"2008","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.leukres.2023.107021_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107021_bib16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"35","key":"10.1016\/j.leukres.2023.107021_bib17","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107021_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107021_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"issue":"27","key":"10.1016\/j.leukres.2023.107021_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/newbio232031a0","article-title":"New technique for distinguishing between human chromosomes","volume":"232","author":"Sumner","year":"1971","journal-title":"Nat. New Biol."},{"issue":"7","key":"10.1016\/j.leukres.2023.107021_bib21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.ejhg.5201410","article-title":"Hardy\u2013Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power","volume":"13","author":"Salanti","year":"2005","journal-title":"Eur. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.leukres.2023.107021_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1471-4914(03)00030-3","article-title":"Genetic associations: false or true?","volume":"9","author":"Ioannidis","year":"2003","journal-title":"Trends Mol. Med."},{"issue":"12","key":"10.1016\/j.leukres.2023.107021_bib23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/ng1474","article-title":"'Racial'differences in genetic effects for complex diseases","volume":"36","author":"Ioannidis","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2023.107021_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2019.04.011","article-title":"First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: age and dose still matter","volume":"81","author":"Belohlavkova","year":"2019","journal-title":"Leuk. Res"},{"issue":"4","key":"10.1016\/j.leukres.2023.107021_bib25","first-page":"1727","article-title":"Effect of age and sex under imatinib mesylate therapy on chronic myeloid leukaemia patients: a pilot study from India","volume":"8","author":"Singh","year":"2017","journal-title":"Int J. Pharm. Sci. Res."},{"key":"10.1016\/j.leukres.2023.107021_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.leukres.2019.05.012","article-title":"Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients","volume":"82","author":"Vasconcelos","year":"2019","journal-title":"Leuk. Res"},{"issue":"4","key":"10.1016\/j.leukres.2023.107021_bib27","first-page":"17","article-title":"Association of MDR1 gene polymorphism (G2677T) with chronic myeloid leukemia","volume":"2","author":"Sailaja","year":"2010","journal-title":"Biol. Med."},{"issue":"2","key":"10.1016\/j.leukres.2023.107021_bib28","first-page":"121","article-title":"Lack of Association between C1236T, G2677T\/A and C3435T variants of the ABCB1 gene and imatinib response in iranian chronic myeloid leukemia patients","volume":"32","author":"Khosravi","year":"2021","journal-title":"J. Sci. Islam Repub. Iran."},{"issue":"1","key":"10.1016\/j.leukres.2023.107021_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-12-383","article-title":"The contribution of the ABCG2 C421A polymorphism to cancer susceptibility: a meta-analysis of the current literature","volume":"12","author":"Chen","year":"2012","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2023.107021_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.26436","article-title":"A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk","volume":"131","author":"Campa","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2023.107021_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ijc.21187","article-title":"Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma","volume":"117","author":"Korenaga","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2023.107021_bib32","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/carcin\/bgm113","article-title":"BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma","volume":"28","author":"Hu","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.leukres.2023.107021_bib33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mgene.2016.11.002","article-title":"Association of genetic polymorphisms of the ABCG2, ABCB1, SLCO1B3 genes and the response to Imatinib in chronic myeloid leukemia patients with chronic phase","volume":"11","author":"Nair","year":"2017","journal-title":"Meta gene"},{"issue":"7","key":"10.1016\/j.leukres.2023.107021_bib34","article-title":"Influence of glutathione S\u2010transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response","volume":"7","author":"Rostami","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"issue":"1","key":"10.1016\/j.leukres.2023.107021_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.29252\/ibj.25.1.54","article-title":"Impact of ABCB1 gene polymorphisms and smoking on the susceptibility risk of chronic myeloid leukemia and cytogenetic response","volume":"25","author":"Mohammadi","year":"2021","journal-title":"Iran. Biomed. J."},{"key":"10.1016\/j.leukres.2023.107021_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tox.2016.07.011","article-title":"Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate","volume":"363","author":"Sayyed","year":"2016","journal-title":"Toxicology"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:29Z","timestamp":1758935009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":36,"alternative-id":["S0145212623000061"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107021"}}